Emma L. Johnston
Isleworth, ENG TW76AF, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Exome sequencing directly implicates 68 genes in inflammatory bowel disease.
Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study.
Journal: Journal of Crohn's & colitis
Published: August 20, 2025
Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn's disease in the UK: a multicentre retrospective cohort study.
Journal: BMJ open gastroenterology
Published: May 23, 2025
Vedolizumab: what is the benefit from increasing the dose frequency?
Journal: Drug and therapeutics bulletin
Published: November 28, 2022
Prescribing for pregnancy: inflammatory bowel disease.
Journal: Drug and therapeutics bulletin
Published: January 28, 2022
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.
Journal: Frontline gastroenterology
Published: May 10, 2021
Anti-Mycobacterium paratuberculosis (MAP) therapy for Crohn's disease: an overview and update.
Journal: Frontline gastroenterology
Published: March 16, 2020
Promoter orientation of the immunomodulatory Bacteroides fragilis capsular polysaccharide A (PSA) is off in individuals with inflammatory bowel disease (IBD).
Journal: Gut microbes
Published: February 09, 2019
Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
Journal: Frontline gastroenterology
Published: September 06, 2017
Utilisation of anti-TNF levels in a UK tertiary IBD centre.
Journal: Frontline gastroenterology
Published: July 27, 2016
Last Updated: 09/26/2026